Trials / Unknown
UnknownNCT05851092
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
A Single Arm, Open, Multicenter Phase I Clinical Study on the Safety, Tolerance, and Pharmacokinetics of HRS-2189 Single Drug in Patients With Advanced Malignant Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-2189 Tablets | HRS-2189 Tablets |
Timeline
- Start date
- 2023-05-26
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-05-09
- Last updated
- 2023-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05851092. Inclusion in this directory is not an endorsement.